Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study
| Autor: | And Vivek Subbiah, Homer A. Macapinlac, David S. Hong, Kalevi Kairemo, Shreyaskumar Patel, Anthony P. Conley, Elmer B Santos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
C-Met
sarcoma medicine.medical_treatment Clinical Biochemistry Article 030218 nuclear medicine & medical imaging Targeted therapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine 18f-fdg pet ct medicine In patient PET-CT Chemotherapy lcsh:R5-920 business.industry Soft tissue 18F-FDG PET CT medicine.disease 18F-FLT PET/CT targeted therapy mdm-2 c-met chemistry 030220 oncology & carcinogenesis 18f-flt pet/ct Sarcoma sense organs Molecular imaging business Nuclear medicine lcsh:Medicine (General) |
| Zdroj: | Diagnostics, Vol 10, Iss 3, p 125 (2020) Diagnostics Diagnostics; Volume 10; Issue 3; Pages: 125 |
| ISSN: | 2075-4418 |
| Popis: | Although 3′-deoxy-3′[(18)F]-fluorothymidine (FLT)-positron emission tomography (PET) has been utilized for tumor response assessment to neoadjuvant chemotherapy in soft tissue sarcomas, it has not been exploited for the assessment of early response to systematically targeted therapies. Herein, we investigated the 18F-FLT PET/CT kinetics in patients with sarcoma who received targeted therapies. Among 15 patients with sarcoma who underwent 18F-FLT PET/CT, 5 patients (33%) patients were imaged at three time points: At baseline and at 1−15 weeks (MDM2-inhibitor treatment), and 10 patients (67%) were imaged twice: At baseline and at 1−4 weeks (MDM2 inhibitor, n = 5; c-met inhibitor n = 5). The patients with sarcoma had a total of 18 identifiable tumors. Twelve of 15 patients (80%) demonstrated 18F-FLT concentrations changes early, i.e., at 1−4 weeks. Eight patients responded (53.3%), four patients progressed (26.7%) based on FLT change of more than 10% increase, and three patients (20%) demonstrated no change. 18F-FLT PET/CT may be used for early response imaging to molecularly targeted therapies in patients with sarcoma. Further larger studies in specific sarcoma sub-types are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|